Biotech Daily

Friday October 30, 2026

Daily news on ASX-listed biotechnology companies

*** ASX UP, BIOTECH DOWN: CYCLOPHARM UP 10%; 4D MEDICAL DOWN 26%**

*** RESMED RECORD Q1 REVENUE UP 6% TO $2b; PROFIT UP 12% TO $572m**

*** DR BOREHAM'S CRUCIBLE: STARPHARMA HOLDINGS**

*** CLINUVEL FILES NEURACTHEL INSTANT IN EUROPE**

*** IMPEDIMED Q1 RECEIPTS UP 22% TO $4m**

*** EPSILON 9-MONTH RECEIPTS UP 68% TO $11m**

*** CYNATA UNDERWRITTEN RIGHTS RAISE $913k**

*** PYC OPTIONS RAISE $918k**

*** TGA: CDA, DR BENJAMIN JANSEN TO PAY $7m FOR MARIJUANA ADS**

*** VITASORA US COMMUNITY CARE DEAL; $3m PETERS LOAN**

*** EPIMINDER: FDA EXPANDS MINDER EPILEPSY MONITOR AGE RANGE**

*** CLEVER CULTURE 'CAPITAL RAISING' TRADING HALT**

*** NOVA EYE AGM 64% BLOCK DIRECTOR RAHMON COUPE**

*** POLYNOVO AGM 26% OPPOSE DR CHARMAINE GITTLESON**

*** EPIMINDER AGM 8% OPPOSE PLACEMENT CAPACITY**

*** BOTANIX POTENTIAL BOARD SPILL AGM**

*** CURVEBEAM 44% BOARD FEE HIKE, 1.5m DIRECTOR SHARES AGM**

*** CHIMERIC POTENTIAL BOARD SPILL AGM**

*** ADALTA 151m BOARD LOAN SHARES AGM**

*** VITASORA 50-TO-1 CONSOLIDATION AGM**

*** PAYNE MEDIA TAKES 7.5% OF MEDICAL DEVELOPMENTS**

*** INOVIQ: DR GEOFF CUMMING, MARY HARNEY OUT; ANDREW CHAPMAN IN**

*** IMAGION LOSES DIRECTOR, CO SEC MELANIE LEYDIN; CO-CO SECS**

*** TROY LAMB REPLACES COMPUMEDICS CFO, CO SEC DAVID LAWSON**

*** CYNATA APPOINTS FORMER M-D DR KILIAN KELLY CONSULTANT**

MARKET REPORT

The Australian stock market was up 0.18 percent on Friday October 30, 2026, with the ASX200 up 16.3 points to 8,908.1 points. Fourteen of the Biotech Daily Top 40 companies were up, 20 fell, five traded unchanged and one was untraded.

Cyclopharm was the best, up four cents or 10.4 percent to 42.5 cents, with 133,640 shares traded. EBR climbed 8.3 percent; Proteomics and Starpharma were up more than four percent; Imricor and Optiscan improved more than three percent; Aroa, Compumedics, Orthocell and Polynovo rose more than two percent; Artrya, Cochlear, CSL, Nanosonics and Neuren were up one percent or more; with Emvision and Resmed up by less than one percent.

4D Medical led the falls, down 84 cents or 25.6 percent to $2.44, with 24.3 million shares traded. Botanix lost 16.7 percent; Impedimed fell 11.1 percent; Imugene and Micro-X were down more than seven percent; Atomo and Clarity shed six percent or more; Amplia lost 5.6 percent; Alcidion fell 4.35 percent; Prescient and Saluda were down more than three percent; Actinogen, Dimerix, Mesoblast, Syntara and Telix shed more than two percent; Clinuvel and Medical Developments were down more than one percent; with Avita, Pro Medicus and Racura down by less than one percent.

RESMED

Resmed says record revenue for the three months to September 30, 2026 was up 5.9 percent to $US1,414,814,000 ($A2,011,260,000), with net profit after tax up 11.5 percent to $US418,000,000 ($A572,000,000).

Resmed cited both US generally accepted accounting principles (GAAP) and non-GAAP data, saying it used non-GAAP information because it provided better insight when evaluating performance from core operations and provided consistent financial reporting. This report quotes the non-GAAP data.

The company said revenue was “primarily driven by strong demand across sleep devices and masks and accessories”, up 8.75 percent in the Americas to $US833,000,000, with no life support device revenue compared to $US9,000,000 in the prior corresponding period.

Resmed said revenue from sleep product sales in the rest of the world rose 11.9 percent to $US423,000,000, with life support sales down 82.35 percent to $US3,000,000 from $US17,000,000 in the previous corresponding period.

The company said it would pay shareholders an unfranked dividend of 6.6 US cents per US share, up from 6.0 US cents per share in the prior corresponding period, with a record date of November 12 and a payment date of December 17, 2026.

There are 10 Resmed Chess depository instruments (CDIs) per US share.

Resmed said non-GAAP diluted earnings per share were up 14.1 percent to $US2.91, and that it had cash and cash equivalents of $US1,010,742,000 at September 30, 2026 compared with $US1,383,848,000 at September 30, 2025.

Resmed chair and chief executive officer Mick Farrell said the company began 2026-’27 “with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business”.

“Looking ahead to the rest of [2026-’27], we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home,” Mr Farrell said.

Resmed was up 13 cents or 0.4 percent to $35.51 with 2.9 million shares traded.

DR BOREHAM'S CRUCIBLE: STARPHARMA HOLDINGS

By TIM BOREHAM

ASX code: SPL

Share price: 45 cents

Shares on issue: 479,739,115

Market cap: $215.9 million

Chief executive officer: Cheryl Maley

Board: Rob Thomas (chair), Ms Maley, David McIntyre, Lynda Cheng, Dr Jeff Davies, Dr Russell Basser (Mr Thomas retires as chairman, at the November 6 AGM but remains a director. Dr Basser assumes the chair)

Financials (year to June 2026): revenue $12 million (up 145%), net loss $7.5 million ($10 million deficit previously), cash balance $44.5 million (as of August 11)

Major shareholders: Allianz SE 11.8%, Rhuroin Pty Ltd 9.52%, Ajava Holdings 7.26%, Dalkeith Securities 4.99%, Ingot Capital Investments 1.77%

As with a stand-up comedian performing before an audience of accountants – or, even worse, actuaries – drug developers face a tough crowd.

This was starkly evidenced last week with Starpharma, which faced a chorus of 'boos' from investors after announcing it would increase its minority 22.5 percent stake in a key joint venture (JV), Petalion Therapeutics, to a controlling 66 percent.

Investors delivered the unfunny punchline, sending Starpharma shares down by more than 30 percent on the day. Starpharma CEO Cheryl Maley said she was "completely surprised" by the reaction.

A likely reason for the angst is the perception that the JV partner, the European venture capital fund Medicxi, was stepping back from Petalion's oncology drug development program.

"That's absolutely not the case," Ms Maley said.

She said the company's involvement always was going to be "tranched", with the majority ownership move stemming from months of negotiations.

"This [increased stake] was not gifted to us," she said. "We have worked hard over the last few months to get this outcome".

As it happens: months of hard labor spoiled by a few mad minutes of share trading.

Success DEP-ends on one thing

Despite corporate tweakings over the years, Starpharma's constant reason for being has been its dendrimer enhanced product (DEP) platform.

It's all a matter of how the DEPs are used.

Dendrimers are nanoscale polymers aimed at improving drug efficacy and reducing side effects (such as bone marrow toxicity and hair loss).

Starpharma listed in September 2000 at the fag-end of the tech boom, as a Paul Keating-era pooled development fund (PDF).

The company shed this structure, which could be a pity as a PDF doesn't pay income tax or capital gains tax at revenue-producing stage.

Starpharma had an agricultural chemical division, which it sold to Canadian agri-giant Agrium in 2017 for $35 million.

With a honed focus on human health, Starpharma commercialized its first DEP based product, Vivagel, as a condom coating in 2011 with Japan's Okamoto Industries and later launched Vivagel BV for bacterial vaginosis locally in April 2019 and then in Europe and Britain.

The company had a contract with Ansell to treat condoms with Vivagel, but this ended in 2016 when Ansell sold its 'sexual health' arm.

Former veterinarian Dr Jackie Fairley became CEO in July 2006 and held the role for 17 years.

Holding a science degree majoring in human physiology, Ms Maley started out in a research role at CSIRO. She then had 25 years in the pharmaceutical sector, including as Novartis' Australia and New Zealand head of oncology.

Ms Maley was on the board of ASX-listed radio-pharmaceutical peer Clarity Pharmaceuticals, but ceded that role when she took on the Starpharma top job.

Staying focused … on diversity

Starpharma is toeing a delicate line between having so many programs that it lacks focus and carrying the risk of a single asset play.

Ms Maley says recent high-profile, late-stage clinical trial disasters highlight the inherent risks of drug development.

"I feel incredibly bad for those companies because it's hard when so much time, effort, money, and patient involvement have been invested," she says.

In the wake of such binary outcomes, Starpharma has ensured it has multiple options.

After clocking on as CEO in January 2024, Ms Maley oversaw the signing of no fewer than three oncology partnerships (see below).

She also identified the company as being too unfocused and “parked” three legacy oncology programs. The company also has strongly embraced radio-pharmacy.

Pharma finds a wife

In April 2024, the company partnered with European venture capitalist Medicxi Ventures to form the UK based Petalion.

Medicxi committed to up to $US25 million ($A38 million) to fund the joint venture (JV) Starpharma earned its initial 22.5 percent Petalion stake by providing intellectual property.

Starpharma earns fees for research and development services, while continuing to own the background intellectual property.

Indeed, Starpharma upped its stake with a $3 million cash payment and $2 million of such services.

Ms Maley says that as well as helping Starpharma to control its own destiny, controlling Petalion enables it to be more forthcoming with shareholders about what the JV actually does.

Hence, we now know the key program relates to a differentiated fibroblast activation protein (FAP). The program is all about adding a FAP-targeted dendrimer drug to Starpharma’s box of tricks.

Medicxi’s approach is to set up single asset companies, bring in new investors and seek a lucrative exit within three to four years.

In October 2025, Starpharma announced a collaboration and licencing agreement with Genentech.

The deal involved a $US5.5 million upfront payment to Starpharma, with up to $US564 million in potential milestones (plus royalties).

The Genentech agreement involves a “limited number” of undisclosed oncology targets.

Starpharma remains free to licence its technology to other parties, beyond these cancers.

“Our goal was to go as narrow as possible and we’re really comfortable with where we landed with negotiations,” Ms Maley said.

Days later the company struck an option agreement with the ASX-listed Radiopharm Theranostics. Radiopharm is looking at developing a treatment that combines DEP with one of its numerous targeted therapy candidates.

In July, Radiopharm paid a $500,000 option fee to Starpharma and is mulling whether to licence the undisclosed program. If so, Starpharma could receive up to $91 million in milestones (plus royalties).

Meanwhile, Starpharma is seeking partners for its ‘old’ (non-nuclear) DEP oncology programs involving irinotecan (colorectal cancer) and cabazitaxel (prostate cancer). The company canned a third program (docetaxel).

Going nuclear

Radio-therapies are a hot research and development area – especially in oncology – but the company isn’t straying from its dendrimer roots.

The idea is that DEPs add to the efficacy of radio-therapies by enabling the treating agent to get to the tumor quickly and precisely.

Starpharma is focused on a planned first in human, phase I study of its candidate DEP human epidermal growth factor receptor-2 (HER2)-lutetium.

As the name suggests, this one zeroes in on HER-2 positive cancers such as breast and gastric, using lutetium isotopes as the targeting agent.

The company says pre-clinical data showed “strong tumor accumulation and retention, favorable biodistribution and clearance characteristics”. The program focuses on HER-2 positive gastric cancer patients who have failed previous therapy.

Ms Maley notes 75 percent to 80 percent of gastric cancer patients treated with the antibody drug conjugate Enhertu required further treatment after 12 months.

Enrolling up to 15 patients, the phase I trial will focus on the usual safety, bio-availability and pharmaco-kinetic aspects. A dose escalation phase then ensues.

While this sounds dull, Ms Maley said ‘big pharma’ partners were keen to see the bio-availability and safety of initial animal studies replicated in early human studies.

These include the agent rapidly clearing from the blood stream and avoiding the kidneys, while being retained in the tumor.

The company plans to kick-off the trial before the year is out, with a likely readout from the first three or four patients by July 2027.

Ms Maley said while breast cancer is a bigger indication, more treatments are available.

“We would have been another fish in a very competitive pond.”

Viva Vivagel

Once the company's flagship product, Vivagel generates useful revenue.

The over-the-counter Vivagel both treats and prevents bacterial vaginosis (BV), an odiferous condition experienced by about one-third of women (depending on the geography).

BV is treated with prescription antibiotics, but because it's a recurring condition that's far from ideal.

Vivagel is subject to various distribution agreements.

Starpharma also sells a variant called Viraleze, an anti-viral spray claimed to prevent colds if used at the first signs of symptoms.

Viraleze has commonalities with Firebrick Pharma's Nasodine, the spray-based anti-viral formulation of Betadine.

Both Vivagel and Viraleze are registered in more than 35 countries, with the latter sold online in the UK and Europe. For reasons beyond our ken, Vivagel is not approved in the US.

The company also plans to launch Vivagel online.

"On that channel, a very small investment in promotion can have a significant uplift," Ms Maley said.

Finances and performance

In the year to June 2026, Starpharma recorded revenue of $12 million, up 145 percent.

This figure included the $8.3 million Genentech upfront payment. Most of the remainder derived pretty evenly from Vivagel and Viraleze sales.

Starpharma's net loss reduced to $7.5 million, from $10 million previously.

Research and development expense "net of [the Federal Government Research and Development Tax Incentive]" increased by 32 percent, to $11.15 million.

At June 30, the company had cash of $11 million. In July and August, the company raised $32 million in a fully underwritten entitlement (rights) offer.

Unusually, the raising did not include an institutional placement.

"We had 99 percent support; we were blown away by that."

Subscribers paid 57 cents a share, a 25 percent discount. They received one share for every 7.5 shares held.

Ms Maley said the $3 million paid to Medicxi was included in the raising.

The company says its cash runway now extends “into” the financial 2027-’28.

Over the last 12 months, Starpharma shares have ranged between 33 cents in late October 2025 and 87 cents on September 30 this year.

The stock hit an all-time high of $2.36 in February 2021 and troughed at 8.9 cents in August 2024.

Despite last week’s slump, the shares have risen 36 percent over the last 12 months.

Dr Boreham’s diagnosis:

When Ms Maley clocked-on in January 2024, Starpharma shares had lost three-quarters of their value over the previous year.

“There is a strong belief in the value of the dendrimer technology, but there is also an increasing urgency to see a return on that value,” she said.

Most ‘business transformation initiatives’ leave investors cold, so kudos to Ms Maley for overseeing three material partnerships and simplifying the company, as promised.

“We’ve got the HER-2 programs and the three partnerships and the phase II assets, as well as discovery and development work,” Ms Maley said.

The increased Petalion stake means the company enjoys a greater share of the FAP spoils, but presumably would need to tip in more dough if the program advances.

Investors can expect an update on the company’s diverse – but focused – activities at its November 6 annual general meeting in Melbourne.

Ms Maley points to potential non-oncology DEP uses such as neurological applications, given its ability to transcend the blood-brain-barrier.

“But first we must hit the milestones for our existing partnerships,” she says.

“It’s one thing to have the agreements, but we actually have to deliver … to get the value from them.”

Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. He’s often so funny he leaves his audience in stitches, but sadly it’s unintentional

CLINUVEL PHARMACEUTICALS

Clinuvel says it has filed its Neuracthel Instant branded generic formulation of tetracosactide, a synthetic adrenocorticotropic hormone, to European regulators.
Clinuvel said adrenocorticotropic hormones (ACTH) belonged to the family of melanocortins, with ACTH products approved as systemic therapies in the US for 19 conditions including infant spasms and acute exacerbations of multiple sclerosis.
Clinuvel fell 11 cents or 1.5 percent to $7.22.

IMPEDIMED

Impedimed says receipts from customers for the three months to September 30, 2026 were up 22.4 percent to $4,213,000, compared to the previous corresponding period.
Impedimed said receipts were from sales of its Sozo bio-impedance spectroscopy for breast-cancer-related lymphoedema, heart health and body composition.
The company said Sozo total contracted value fell 18.5 percent to $4.4 million, “driven by lower volume of contracts due for renewal”.
Impedimed said it had a cash burn of $2,462,000 for the three months, with cash and cash equivalents of $11,579,000 at September 30, 2026 compared to $22,989,000 at September 30, 2025.
Impedimed fell 0.05 cents of 11.1 percent to 0.4 cents with 7.7 million shares traded.

EPSILON HEALTHCARE

Epsilon says receipts from customers for the nine months to September 30, 2026 were up 68.4 percent to $10,583,000, compared to the prior corresponding period.
Epsilon said receipts for the three months rose 33.5 percent to $3,898,000, “supported by increasing demand” for its contract development and manufacturing operations, Epsilon Clinics and Epsilon Pharmacy business”.
Previously, the company said its businesses included the sale and distribution of medical marijuana (BD: May 12, 2023).
Today, Epsilon said it had a $500,000 three-month cash burn, with cash and equivalents of $997,000 at September 30, 2026 compared to $643,000 at the prior year and had a $2,100,000 loan at 18 percent yearly interest.
Epsilon fell 0.1 cents or 5.8 percent to two cents.

CYNATA THERAPEUTICS

Cynata says it has raised about $912,962 at one cent a share in a three-for-eight, fully-underwritten, pro-rata, renounceable entitlement offer (BD: Oct 8, 2026).
Cynata said it had applications for about $235,150, with the shortfall taken up by the underwriter Caravel Securities.
Cynata said participants would receive one attaching option for every three shares issued, exercisable at two cents each within 30 months of the issue date.
Cynata was unchanged at 1.2 cents.

PYC THERAPEUTICS

PYC says it has raised $918,000 on the issue of 540,000 shares following the exercise of options at $1.70 each, expiring October 26, 2026.
PYC fell 5.5 cents or 2.8 percent to $1.88 with 4.7 million shares traded.

AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION
VITURA HEALTH (FORMERLY CRONOS AUSTRALIA)

The TGA says the Federal Court has ordered CDA Clinics Queensland Pty Ltd pay $6.5 million and former director Dr Benjamin Jansen $450,000 in civil penalties.

Last year, Vitura said it had "discontinued funding the defence of CDA Clinics [Queensland]" in the proceedings brought by the TGA (BD: Jan 19, 2025).

A media release today from the Australian Therapeutic Goods Administration (TGA) said the Federal Court in Brisbane ordered the company to pay $6.5 million in civil penalties "for the unlawful advertising of medicinal cannabis to the public in breach of the Therapeutic Goods Act (1989)".

The Administration said the Court had ordered "Dr Benjamin Jansen, the former director of CDA Clinics, to pay $450,000 in civil penalties for his role in aiding and abetting CDA Clinics' conduct".

The TGA said the Court had found "that CDA Clinics promoted the use of medicinal cannabis products, including unapproved and prescription-only medicines, that were not entered in the Australian Register of Therapeutic Goods, in breach of the [Therapeutic Goods Act (1989)]".

The Administration said "the advertisements also unlawfully promoted the use of medicinal cannabis for the treatment of serious diseases, conditions and disorders … [and that] such references are known as restricted representations or prohibited representations and are not allowed to be included in advertising for therapeutic goods, unless an approval or permission is given by the TGA".

In 2021, the then Cronos said it acquired the Varsity Lakes, Gold Coast, Queensland-based CDA Clinics (formerly Cannabis Doctors Australia) (BD: Sep 14, Dec 16, 2021).

At the time, Cronos told Biotech Daily that Dr Charlie Jansen and Dr Benjamin Jansen were founders and former doctors with Cannabis Doctors Australia.

In 2022, Cronos said Matua Charlie Jansen called for the removal of directors, chief executive officer Rodney Cocks and chief commercial officer Guy Headley; chief medical officer and director Dr Benjamin Jansen had "ceased his position"; and it had a section 249N notice to appoint Dr Benjamin Jansen as a director (BD: Sep 20, 23, 28, 2022).

Later, the then Cronos said it had resolved its issues with Elizabeth and Dr Benjamin Jansen, and they would vote their 129,890,570 shares "in accordance with the board's recommendations" (BD: Nov 28, 2022).

At that time, the company said it and co-founder and former director Dr Benjamin Jansen "acknowledge that their previous statements may have caused offence to each other, and both parties regret that the relationship between them had started to erode".

In 2023, the TGA said it began proceedings against Vitura's CDA Clinics Qld Pty Ltd for the alleged unlawful advertising of cannabidiol (CBD) (BD: Dec 5, 2023).

The Federal Court of Australia website said that in delivering her judgement Justice Berna Collier said "the advertisements former part of a deliberate commercial strategy".

"The advertisements were neither inadvertent nor isolated but rather formed part of the manner in which CDA conducted its business," Justice Collier said.

"Clearly, Dr Jansen was not a passive director removed from the conduct of the business … rather, he was the individual principally responsible for the development and operation of the CDA model and the website during the relevant period," she said.

"Although I accept that CDA may not have deliberately set out to contravene the [Therapeutic Goods] Act, I am satisfied that CDA's approach to compliance with the statutory regime was nevertheless inadequate," Justice Collier said.

Vitura was up 0.2 cents or 11.1 percent to two cents with 1.1 million shares traded.

VITASORA HEALTH (FORMERLY RESPIRI)

Vitasora says it has a patient monitoring contract with Fellsmere, Florida's Treasure Coast Community Health and an up-to $3.0 million loan from Peters Investments.
Vitasora said Treasure Coast had seven locations in Florida and about 31,000 patients, providing an initial addressable Medicare population of about 9,000 patients.
The company said the agreement included its chronic care and principal care management for remote patient monitoring, with enrolments to begin next month.
Vitasora said its current Florida-based chronic care management clients generated about $US70 to $US100 ($A99 to $A142) per patient per month, depending on care needs.
Biotech Daily calculates that the 9,000 Medicare patients under the Treasure Coast agreement amounted to between $891,000 and $202,000 in monthly revenue.
In its Appendix 4C today, the company said customer receipts for the three months to September 30, 2026 were $1,015,000, with a three-month cash burn of $2,081,000 and cash on hand of $862,000, leaving it about 0.41 in available funding.
Vitasora said it had taken a $3.0 million secured loan from substantial shareholder Peters Investments at 12.5 percent yearly interest, repayable within 24 months, with draw-downs conditional on a formal agreement and subject to shareholder approval.
The company said the loan included 208,971,000 options, initially exercisable at 1.2 cents each within four years, subject to adjustment on the issue of shares at a price below the prevailing exercise price, with a minimum exercise price of 0.4 cents.
Vitasora said the funds would "support [Treasure Coast] and other client implementations, care co-ordinator recruitment, patient enrolments and working capital".
The company said a 19.9 percent ownership of Vitasora by Peters on full exercise "remained subject to capitalization verification and applicable approvals" and that the options could not be exercised to the extent that their exercise would breach the 20 percent takeover threshold as stated in the section 606 of the Corporations Act (2001).
Vitasora said loan documents were being finalized, and remained subject to conditions.
Vitasora fell 0.1 cents or 7.7 percent to 1.2 cents.

EPIMINDER

Epiminder says it has US Food and Drug Administration clearance to expand the age range for its Minder monitor system for epilepsy to patients aged 12 years and older.
Last year, Epiminder raised $125 million in an initial public offer to commercialize its FDA-cleared Minder implantable electro-encephalogram (EEG) monitor (BD: Dec 1, 2025).
Today, the company said the original de novo approval was for adults aged 18 years and older and the expanded clearance "broadens the eligible patient population for the technology, enabling US clinicians to offer continuous EEG monitoring to adolescent patients for the first time".
Epiminder managing-director Dr Rohan Hoare said the clearance was "a meaningful step forward for patients and for the epilepsy community".
"Adolescence is a particularly vulnerable period for individuals living with drug-resistant epilepsy, uncontrolled seizures during these years carry profound consequences for development, education, and independence," Dr Hoare said.
"With this clearance, US neurologists can now offer the Minder system to their teenage patients, giving them access to continuous, objective EEG data over the timescales needed to guide real treatment decisions," Dr Hoare said. "We have always believed that every patient who could benefit from continuous EEG monitoring deserves access to it, and this clearance brings us meaningfully closer to that goal."
Epiminder was unchanged at 26.5 cents.

CLEVER CULTURE SYSTEMS (FORMERLY LBT INNOVATIONS)

Clever Culture has requested a trading halt “pending an announcement to the market in relation to a material capital raising”.
Clever Culture said the capital raise would be used to “provide additional funds for the development of a smaller desktop version of the [automated plate assessment system] technology, to expand the product offering to include lower volume sterile drug manufacturing facilities”.
Trading will resume on November 3, 2026, or on an earlier announcement.
Clever Culture last traded at 1.9 cents.

NOVA EYE MEDICAL

Nova Eye says its annual general meeting voted 63.96 percent to defeat the election of director Rahmon Coupe, with both remaining resolutions passed overwhelmingly.
Nova Eye said the election or Mr Coupe was opposed by 53,276,285 votes (63.96%), with 30,024,173 votes (36.04%) in favor.
The company said the remuneration report and election of Dr Thomas Duthy as a director were passed easily by more than 99.49 percent of the meeting in support.
In an Appendix 3Z, Mr Coupe said that he ceased to be a director yesterday.
According to its most recent filing, Nova Eye had 284,921,093 shares on issue, meaning that the vote against Mr Coupe’s election amounted to 18.7 percent of the company, sufficient to requisition extraordinary general meetings.
Nova Eye was unchanged at 15 cents.

POLYNOVO

Polynovo says its annual general meeting passed all four resolutions with up-to 26.08 percent opposed to the election of Dr Charmaine Gittleson as a director.
Polynovo said Dr Gittleson was elected with 62,790,735 votes (26.08%) against and 177,960,129 votes (73.92%) in support.
The company said the remuneration report faced 13.50 percent dissent, with the election of directors Dean Phizacklea and Andrew Price passing easily.
According to its annual report, Polynovo had 690,842,991 shares on issue, meaning that the votes against Dr Gittleson’s election amounted to about 9.1 percent of the company, sufficient to requisition extraordinary general meetings.
Polynovo was up 2.5 cents or 2.8 percent to 90.5 cents with 1.4 million shares traded.

EPIMINDER

Epiminder says its annual general meeting has approved all four resolutions with up-to 8.16 percent against the additional 10 percent placement capacity.
Epiminder said the placement capacity was opposed by 13,311,795 votes (8.16%), with 149,905,001 votes (91.84%) in favor.
The company said the election of Robert Klupacs as a director faced 7.30 percent dissent, with the remuneration report, auditor appointment and issue of options to managing-director Dr Rohan Hoare easily passed by more than 98.55 percent of the meeting in favor.
According to its annual report, Epiminder had 216,671,652 shares on issue, meaning the votes against the placement capacity amounted to 6.1 percent of the company, sufficient to requisition extraordinary general meetings.

BOTANIX PHARMACEUTICALS

Botanix says its annual general meeting will vote on the remuneration report and a conditional spill resolution.

Last year, Botanix said its annual general meeting defeated the remuneration report with 73.21 percent against, with the remaining resolutions passed (BD: Nov 5, 2025).

Under the Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 any company with a vote of 25 percent or more against the remuneration report in two successive annual meetings must vote on a board spill.

Today, the company said shareholders would vote to re-elect Vincent Ippolito, Andrew Bickley and Graeme Morissey as directors, approve the employee awards plan and additional 10 percent placement capacity.

The meeting will be held at Level 9, Mia Yellagonga Tower 2, 5 Spring Street, Perth on November 30, 2026 at 9.30am (AWST).

Botanix fell 0.2 cents or 16.7 percent to one cent with 39.2 million shares traded.

CURVEBEAM A.I.

Curvebeam says its annual general meeting will vote to increase the aggregate director fee pool by 44.4 percent to $650,000 and issue 1,542,275 shares to directors.

Curvebeam said the increase in the aggregate director remuneration provided “the company with the ability to attract and retain directors of the highest calibre, whilst incurring a cost that is acceptable to shareholders”.

The company said investors would vote to issue chair Robert Lilley 593,662 shares, executive director Dr Yu Peng 548,544 shares and director Patrick Fisher 400,069 shares, in addition to their cash fees.

Curvebeam said shareholders would vote to adopt the remuneration report, elect Mr Lilley, Mr Fisher, Dr Peng and Daniel Pryor as directors, ratify the prior issue of shares, advisory shares and broker options, renew the omnibus incentive plan and approve the additional 10 percent placement capacity.

The meeting will be held online on November 30, 2026 at 9am (AEDT).

Curvebeam was unchanged at 1.7 cents with 2.5 million shares traded.

CHIMERIC THERAPEUTICS

Chimeric says its annual general meeting will vote on the remuneration report and a conditional board spill resolution.

Last year, Chimeric said up-to 90.03 percent of its annual general meeting defeated the re-election and issue of incentive options to chair Paul Hopper and voted a remuneration report first strike (BD: Nov 25, 2025).

Under the Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 a company with a vote of 25 percent or more against the remuneration report in two successive annual meetings must vote on a board spill.

Today, the company said the meeting would vote to re-elect Phillip Hains as a director and approve the additional 10 percent placement capacity.

The meeting will be held online on November 30, 2026 at 11am (AEDT).

Chimeric was in a suspension and last traded at 0.3 cents.

ADALTA

Adalta says its annual general meeting will vote to issue 151,451,252 interest free loan shares to its chair, managing-director and two directors Fadi Diab and Michelle Burke.
Adalta said investors would vote to issue managing-director Dr Tim Oldham and chair Dr Paul MacLeman 73,947,030 loan shares and 37,352,110 loan shares, respectively, as well as 20,076,056 loan shares, each, to Fadi Diab and Michelle Burke.
The company said the loan shares were “intended to preserve the company’s cash resources, align the participating directors’ interests with those of shareholders and support their retention and incentivization in their respective roles with the company”.
The company said investors would vote to adopt the remuneration report and elect Fadi Diab and Dr Paul MacLeman as directors.
The meeting will be held at Piper Alderman, Level 23, 459 Collins Street, Melbourne on November 30, 2026 at 2pm (AEDT).
Adalta was unchanged at 0.25 cents with 52.8 million shares traded.

VITASORA HEALTH (FORMERLY RESPIRI)

Vitasora says its annual general meeting will vote to approve a 50-to-one consolidation to provide a “more effective capital structure … and more appealing share price”.
Vitasora said the meeting would vote to adopt the remuneration report, elect directors Marjan Mikel, Nicholas Smedley and Jonathan Adams, ratify the prior issue of shares, approve the issue of placement shares to directors, renew the employee share option plan and approve the 10 percent placement facility.
The meeting will be held at Level 3, 80 Dorcas Street, Melbourne on November 30, 2026 at 2pm (AEDT).

MEDICAL DEVELOPMENTS

Payne Media Pty Ltd says it has increased its substantial shareholding in Medical Developments from 7,100,382 shares (6.30%) to 8,500,080 shares (7.55%).
The Albury, New South Wales-based Payne Media said that it bought shares between July 15 and October 26, 2026, with the largest purchase 200,000 shares on September 28, 2026 for $88,000, or 44 cents a share.
Medical Developments fell half a cent or 1.35 percent to 36.5 cents.

INOVIQ

Inoviq says directors Dr Geoff Cumming and Mary Harney will retire at its annual general meeting on November 25, with Andrew Chapman appointed a director from November 2.
Inoviq said Mr Chapman was Merchant Funds Manager founder, had more than 25 years of experience in financial services and was currently a director of Argent and Neurotech, Cycliq Group chair and held a Bachelor of Commerce.
Inoviq was up half a cent or 3.7 percent to 14 cents.

IMAGION BIOSYSTEMS

Imagion says director and company secretary Melanie Leydin has resigned, effective from today, with Mariia Skorikova and Tony Di Pietro joint company secretaries.
Imagion was unchanged at 0.5 cents.

COMPUMEDICS

Compumedics says it has promoted Troy Lamb to chief financial officer and company secretary, from November 1, 2026, with David Lawson continuing as finance director.
Compumedics said Mr Lawson had worked for the company for 26 years and would continue as finance director, working with the board and management on its "financial strategy, business operations and key growth initiatives".
The company said Mr Lamb had been deputy chief financial officer and had more than 20 years of financial and commercial experience including with ASX-listed companies and held a Master of Business Administration from the University of Melbourne.
Compumedics was up half a cent or 2.1 percent to 24 cents.

CYNATA THERAPEUTICS

Cynata says former managing-director and current director Dr Kilian Kelly will provide consultancy services, to be paid $8,333 month in equal amounts of cash and scrip.
In July, Cynata said that, following two negative trial results, all employees, would be made redundant, including Dr Kelly, with a reduced board to evaluate future options (BD: Jul 6, 2026)
Today, the company said it had entered an agreement with Lir Bio Advisory Pty Ltd for provision of consultancy services by Dr Kelly, with the issue of consideration shares subject to shareholder approval.
Cynata said Dr Kelly's appointment as a consultant was effective from November 1, 2026 with no fixed term as an independent contractor.
The company said Dr Kelly would "oversee maintenance of the company's existing assets and regulatory/compliance obligations related to those assets, assist with identification, review and evaluation of new assets and opportunities to realize value from the company's existing assets".